Amazon workers in Minnesota and Germany are striking as Prime Day kicks off, in a stand against working conditions and wage practices. The action in Minnesota represents the...Retailread more
Treasury Secretary Steven Mnuchin is raising red flags ahead of Facebook's proposed cryptocurrency launch.Marketsread more
Some White House officials expect the Cabinet secretary, who has known the president for years, to depart as soon as this summer.Politicsread more
Epstein is accused of sexually exploiting dozens of underage girls from 2002 through 2005 at his New York and Florida residences. He is a former friend of Presidents Donald...Politicsread more
When you think of Prime Day, you might be thinking about deals on Instant Pots and Amazon Echo devices — not half-off dresses and designer heels. But the market for apparel...Retailread more
David Marcus, the head of Facebook's digital currency project, said the company expects Libra will drive more advertising revenue for the company.Technologyread more
Boeing met with aircraft leasing firms and financiers in New York as the grounding of its popular 737 Max planes drags on with no clear timeline for getting the planes back in...Aerospace & Defenseread more
Both companies report earnings on Aug. 8, so the CBS and Viacom boards have set that as a natural deadline to agree to a merger. Price won't be discussed by the companies...Technologyread more
The Food and Drug Administration "stands ready" to start reviewing e-cigarettes amid a teen vaping "epidemic," acting Commissioner Ned Sharpless said Monday in a statement.Health and Scienceread more
US oil companies on Monday began restoring some of the more than nearly 74% production shut at U.S. Gulf of Mexico platforms ahead of Hurricane Barry, the US offshore drilling...Energyread more
The Guggenheim CIO says he had been approached by the White House about possibly joining the Federal Reserve.The Fedread more
British pharmaceutical giant AstraZeneca reported a loss for the fourth quarter of 2014, but stressed that it was on track to return to growth by 2017.
The company, which saw off a £69 billion ($105 billion) takeover attempt from Pfizer of the U.S., reported a quarterly net loss of $321 million, a 38 percent drop from last year's $1.5 billion net profit, while revenue for the last three months of the year fell 2 percent on the same period a year ago to $6.68 billion.
AstraZeneca also confirmed it would would buy Actavis's branded respiratory business in the U.S. and Canada for an initial $600 million plus an additional $100 million. The deal is expected to complete by the end of March.
"With the addition of (respiratory drugs) Tudorza and Daliresp, we will benefit from an immediate boost to revenue in our biggest market, further strengthening our growing respiratory franchise," said Paul Hudson, president of AstraZeneca U.S., in a news release.
The company also declared a second interim dividend of $1.90 per share, bringing the dividend for the full year to $2.80.
The company received a record six product approvals in 2014. These included Duaklir Genuair, a drug used to treat chronic obstructive pulmonary disease, which was approved by the European Commission in November.
The big story for 2014 however was Pfizer's £69 billion ($105 billion) attempted takeover of AstraZeneca. The bid, which failed, would have allowed Pfizer to benefit from lower tax rates and gain a new pipeline of drugs, but was fiercely resisted by AstraZeneca and some U.K. politicians.
On Wednesday, AstraZeneca announced that it had received permission to build a new global R&D center and corporate headquarters in Cambridge, U.K. The purpose-built facility will be located on the Cambridge Biomedical Campus and will house around 2,000 employees. It comes as part of AstraZeneca's plans to improve links to European academic centers.
Commenting on the results, Citi analyst Andrew Baum said that AstraZeneca remained his preferred "buy"-rated global pharmaceutical company, with a price target of £54 ($82).
"We think the market continues to estimate the oncology, immune oncology, autoimmune pipelines and Brilinta PEGASUS data," he said in a research note.
"Although the quality of near-term earnings will likely continue to underwhelm, the dividend remains well covered."
Shares in AstraZeneca opened down 2.74 percent Thursday morning at £45.56.